163 related articles for article (PubMed ID: 34900204)
1. GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.
Du M; Feng J; Tao Y; Pan Q; Chen F
J Healthc Eng; 2021; 2021():7631815. PubMed ID: 34900204
[TBL] [Abstract][Full Text] [Related]
2. The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma.
Pei X; Zhang J; Wu L; Lü B; Zhang X; Yang D; Liu J
Biosci Rep; 2013 Sep; 33(5):. PubMed ID: 23984917
[TBL] [Abstract][Full Text] [Related]
3. DNMT1 mediated promoter methylation of GNAO1 in hepatoma carcinoma cells.
Xu D; Du M; Zhang J; Xiong P; Li W; Zhang H; Xiong W; Liu F; Liu J
Gene; 2018 Jul; 665():67-73. PubMed ID: 29709639
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.
Zhang Y; Liu X; Liu L; Chen J; Hu Q; Shen S; Zhou Y; Chen S; Xue C; Cui G; Yu Z
Dis Markers; 2020; 2020():2514090. PubMed ID: 32399086
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
6. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
7. Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma.
Ding Y; Sun Z; Zhang S; Xu Q; Zhou L; Zhou D; Li Y; Han X; Xu H; Bai Y; Xu C; Ding H; Ge Y; Wang W
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32697317
[TBL] [Abstract][Full Text] [Related]
8. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
9. C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence.
Chen J; Chen J; Gong Y; Zou B; Liu X; Ding L; Huang J; Zhang B; Li J
J Invest Surg; 2020 Dec; 33(10):914-923. PubMed ID: 30907217
[No Abstract] [Full Text] [Related]
10. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines.
Wang XK; Liao XW; Yang CK; Liu ZQ; Han QF; Zhou X; Zhang LB; Deng T; Gong YZ; Huang JL; Huang R; Han CY; Yu TD; Su H; Ye XP; Peng T; Zhu GZ
J Cell Physiol; 2020 Oct; 235(10):7003-7017. PubMed ID: 32037547
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma.
Ruan H; Wang T; Yang C; Jin G; Gu D; Deng X; Wang C; Qin W; Jin H
Sci Rep; 2016 Sep; 6():32421. PubMed ID: 27581744
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma.
Cai J; Tong Y; Huang L; Xia L; Guo H; Wu H; Kong X; Xia Q
Carcinogenesis; 2019 Jul; 40(7):840-852. PubMed ID: 31059567
[TBL] [Abstract][Full Text] [Related]
13. High mRNA Expression of
Cui Z; Xiao L; Chen F; Wang J; Lin H; Li D; Wu Z
Dis Markers; 2021; 2021():9971799. PubMed ID: 34457090
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
16. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
17. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.
Zeng YL; Guo ZY; Su HZ; Zhong FD; Jiang KQ; Yuan GD
World J Gastroenterol; 2019 Dec; 25(48):6902-6915. PubMed ID: 31908394
[TBL] [Abstract][Full Text] [Related]
19. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis.
Geng M; Cao YC; Chen YJ; Jiang H; Bi LQ; Liu XH
World J Gastroenterol; 2012 Mar; 18(12):1328-38. PubMed ID: 22493546
[TBL] [Abstract][Full Text] [Related]
20. Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma.
Liu YB; Gao SL; Chen XP; Peng SY; Fang HQ; Wu YL; Peng CH; Tang Z; Xu B; Wang JW; Deng GL; Li HJ; Feng XD; Qian HR
World J Gastroenterol; 2005 Mar; 11(9):1378-81. PubMed ID: 15761980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
